Dr. Jan Groen is currently the Chairman of Delta Life Sciences, a company that develops and commercialises innovative, high-speed, and cost-effective biosensing instruments and sensor chips. Jan was previously the CEO and Chairman at Intravacc B.V. a contract development and manufacturing organisation for infectious disease and therapeutic vaccines and CEO of MDxHealth, a publicly listed genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in urological cancers. MDxHealth’s genomic tests are setting new standards in prostate and bladder cancer diagnosis, where they have helped over 100,000 patients avoid unnecessary diagnostic procedures.
Jan’s career spans over 25 years in clinical diagnostics and life science global markets. Jan was previously the President and COO of Agendia, responsible for their United States and European diagnostic operations, respectively. Jan is co-founder of ViroClinics and DxOrange and has held numerous management and scientific positions at Focus Diagnostics, a subsidiary of Quest Diagnostics, the Erasmus Medical Centre, and Akzo-Nobel.
Jan has had board mandates in several life science companies. Currently he is the Chairman of Delta Life Sciences (NL), RadiomicsBio (BE) VesicaHealth (USA), and serves on the board of Novigenix SA in (CH), SPL Medical (NL) and Gilbert (NL). Jan holds a PhD in Medical Microbiology from the Erasmus University Rotterdam, a BSc in Clinical Laboratory Studies and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.
LinkedIn
Brings to the Board
Expertise in new product development, including development and successful commercialisation of CE marked and FDA cleared diagnostic products and lab-developed tests in Europe and the USA.